Brexpiprazole

布瑞哌唑

Report date: 2026/05/16 20:00:17
NME

Base Information

Drug NameBrexpiprazole
Drug Alias Namebrexpiprazol布瑞哌唑依匹哌唑brexpiprazolebrexpiprazolum +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsSerotonin 1a (5-HT1a) receptor agonistsDopamine D2 receptor agonists
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor
Therapy Area/IndicationsBipolar I DisorderAgitationStress Disorders, Post-Traumatic +[23] 
Global Approved IndicationsSchizophreniaDepressive Disorder, MajorDepressive Disorder +[4] 
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryUnited States
Original Approved Date2015/07/10
Country/TerritoryBulgariaCanadaUnited States +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHumanis Saglık Anonim SirketiOtsuka Holdings Co LtdOtsuka Pharmaceutical Development & Commercialization Inc +[9] 
Inactive CompaniesZhuhai Livzon Microsphere Technology Co LtdSharp CorpDuke University +[7] 
Active IndicationsAgitationStress Disorders, Post-TraumaticSchizophrenia +[11] 
Inactive IndicationsBipolar I DisorderAutistic DisorderConduct Disorder +[12] 

Other Information

ATC CodeN05AX16
Related LinksWikipediaDrugBankKEGG